Business
OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma
NEW YORK, May 15, 2025--OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced the launch of OS Animal Health, Inc., a wholly owned subsidiary focused on commercializing OST-HER2 for the treatment of canine osteosarcoma.
About this update from Os Therapies Incorporated
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/b5f4db0ad9b03d0217189ed265ee5d1a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/SsLbLgJoUoys2nuPGIuQSQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b5f4db0ad9b03d0217189ed265ee5d1a","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/XgQJxi1GWJ1YD0AiU9HMRA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/b5f4db0ad9b03d0217189ed265ee5d1a","width":1024,"height":512}},"lazy":false},{"type":"text","content":"NEW YORK, May 15, 2025--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced the launch of OS Animal Health, Inc., a wholly owned subsidiary focused on commercializing OST-HER2 for the treatment of canine osteosarcoma.","length":373,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"OST-HER2 market opportunity in canine osteosarcoma exceeds $150 million","length":71,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Recent data in prevention of amputation in frontline canine osteosarcoma and control of metastatic osteosarcoma adds to historical data that supported prior conditional approval related to increase in overall survival (OS) post-amputation","length":238,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Updated commercial manufacturing process to be used in pending new USDA conditional approval application for frontline, metastatic and OS in osteosarcoma","length":153,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":462,"olType":false},{"type":"text","content":"OST-HER2 is an off-the-shelf immunotherapy candidate that has shown positive clinical data in both human pediatric and canine osteosarcoma. Parent company OS Therapies is advancing towards an FDA Accelerated Approval submission, anticipated in the third quarter of 2025, for the prevention of recurrence in pediatric patients with fully resected, lung-metastatic osteosarcoma. Concurrently, its wholly-owned su...